$3.81
0.3610.58%
Last update: 3:37 PM
15 minutes delayed
Aquestive Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Aquestive Therapeutics using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
AQST | Aquestive Therapeutics | -$0.10 | -$0.12 | — | — | $13.24M | $12.38M | — | — | 08/06/2024 | Get Alert |
AQST | Aquestive Therapeutics | $0.11 | -$0.08 | -$0.17 | -112.50% | $11.13M | $12.26M | $12.05M | -1.69% | 05/07/2024 | Get Alert |
AQST | Aquestive Therapeutics | -$0.23 | -$0.08 | -$0.10 | -25.00% | $10.68M | $11.63M | $13.21M | 13.55% | 03/05/2024 | Get Alert |
AQST | Aquestive Therapeutics | -$0.23 | -$0.11 | -$0.03 | 72.73% | $11.46M | $11.51M | $13.00M | 12.96% | 11/06/2023 | Get Alert |
AQST | Aquestive Therapeutics | -$0.36 | -$0.11 | -$0.10 | 9.09% | $13.27M | $10.76M | $13.24M | 23.06% | 08/07/2023 | Get Alert |
AQST | Aquestive Therapeutics | -$0.32 | -$0.19 | $0.11 | 157.89% | $12.27M | $9.94M | $11.13M | 12.01% | 05/02/2023 | Get Alert |
AQST | Aquestive Therapeutics | -$0.38 | -$0.23 | -$0.23 | 0.00% | $11.08M | $10.42M | $10.68M | 2.51% | 03/07/2023 | Get Alert |
AQST | Aquestive Therapeutics | -$0.37 | -$0.30 | -$0.23 | 23.33% | $13.29M | $11.04M | $11.46M | 3.83% | 11/01/2022 | Get Alert |
AQST | Aquestive Therapeutics | -$0.33 | -$0.36 | -$0.36 | 0.00% | $15.35M | $10.57M | $13.27M | 25.50% | 08/02/2022 | Get Alert |
AQST | Aquestive Therapeutics | -$0.41 | -$0.41 | -$0.32 | 21.95% | $11.12M | $10.11M | $12.27M | 21.36% | 05/03/2022 | Get Alert |
AQST | Aquestive Therapeutics | -$0.60 | -$0.47 | -$0.38 | 19.15% | $7.15M | $9.36M | $11.08M | 18.35% | 03/08/2022 | Get Alert |
AQST | Aquestive Therapeutics | -$0.49 | -$0.45 | -$0.37 | 17.78% | $8.26M | $11.01M | $13.29M | 20.68% | 11/02/2021 | Get Alert |
AQST | Aquestive Therapeutics | -$0.07 | -$0.44 | -$0.33 | 25.00% | $21.68M | $9.48M | $15.35M | 61.87% | 08/03/2021 | Get Alert |
AQST | Aquestive Therapeutics | -$0.49 | -$0.43 | -$0.41 | 4.65% | $8.77M | $8.97M | $11.12M | 23.99% | 05/04/2021 | Get Alert |
AQST | Aquestive Therapeutics | -$0.48 | -$0.26 | -$0.60 | -130.77% | $16.42M | $6.25M | $7.15M | 14.38% | 03/09/2021 | Get Alert |
AQST | Aquestive Therapeutics | -$0.54 | -$0.46 | -$0.49 | -6.52% | $12.42M | $8.72M | $8.26M | -5.28% | 11/04/2020 | Get Alert |
AQST | Aquestive Therapeutics | -$0.82 | -$0.43 | -$0.07 | 83.72% | $11.13M | $8.77M | $21.68M | 147.15% | 08/04/2020 | Get Alert |
AQST | Aquestive Therapeutics | -$0.59 | -$0.47 | -$0.49 | -4.26% | $12.64M | $10.07M | $8.77M | -12.96% | 05/05/2020 | Get Alert |
AQST | Aquestive Therapeutics | -$0.56 | -$0.39 | -$0.48 | -23.08% | $16.82M | $15.84M | $16.42M | 3.66% | 03/11/2020 | Get Alert |
AQST | Aquestive Therapeutics | — | -$0.69 | -$0.54 | 21.74% | — | $9.97M | $12.42M | 24.55% | 11/05/2019 | Get Alert |
AQST | Aquestive Therapeutics | — | -$0.62 | -$0.82 | -32.26% | — | $9.18M | $11.13M | 21.23% | 08/06/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $-0.17 | $-0.08 | -112.5 % |
Dec 2023 | 2024-03-05 | $-0.10 | $-0.08 | -25.0 % |
Sep 2023 | 2023-11-06 | $-0.03 | $-0.11 | 72.7 % |
Jun 2023 | 2023-08-07 | $-0.10 | $-0.11 | 9.09 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $12.05M | $12.26M | -1.69 % |
Dec 2023 | 2024-03-05 | $13.21M | $11.63M | 13.6 % |
Sep 2023 | 2023-11-06 | $13.00M | $11.51M | 13.0 % |
Jun 2023 | 2023-08-07 | $13.24M | $10.76M | 23.1 % |
Aquestive Therapeutics (AQST) is scheduled to report earnings on August 6, 2024. The last reported earnings were for reported on May 7, 2024 for Q1.
The Actual EPS was $-0.17, which missed the estimate of $-0.08.
The Actual Revenue was $12.1M, which missed the estimate of $12.3M.
Browse earnings estimates, EPS, and revenue on all stocks.